On Nov. 7, 2024, the U.S. Food and Drug Administration (FDA) granted icometrix clearance for icobrain aria, the first AI software approved for detecting, measuring and grading amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new amyloid-targeting therapies. A large study, needed for FDA clearance, demonstrated that the use of icobrain aria significantly increases the accuracy of ARIA assessments by radiologists and hence allows for safer use of new amyloid-beta targeting therapies for Alzheimer’s disease patients.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now